ArticleJournal of medicinal chemistry2026
Automated DNA-Encoded Library Synthesis and Activity-Based Screening at the Attomole Scale.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
One-bead-one-compound DNA-encoded library (OBOC-DEL) technology enables synthesis and activity-based screening of diverse compound collections but requires complex microfluidic instrumentation and laborious manual bead handling. Here, we execute DEL synthesis on 2.8-μm-dia magnetic beads and encapsulate them in a functionalized polyacrylamide hydrogel to support in-gel activity assays. Magnetic-bead loading capacity was ∼10 amol of small molecule and ∼104 DNA encoding tags per bead. We developed a fully automated magnetic solid-phase synthesis using a KingFisher instrument. Bulk emulsification of DEL beads with assay reagents eliminated the need for microfluidics. Activity-based screening against Factor Xa identified enzyme inhibitors, including the positive control (rivaroxaban, incorporated into the library), which was recovered as the most abundant hit (replicate k class = 14). This ultraminiaturized platform uses commercially available automation and flow cytometry, making OBOC-DEL technology broadly accessible and distributable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.